Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Genetic analysis of aquaporin-4 in neuromyelitis optica.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Neurotrophic and Neuroprotective effects of muscle contraction.
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis.
Prevalence of people who could benefit from augmentative and alternative communication (AAC) in the UK: determining the need.
Interferon β-secreting mesenchymal stem cells combined with minocycline attenuate experimental autoimmune encephalomyelitis.
Developing a Valuation Function for the Preference-Based Multiple Sclerosis Index: Comparison of Standard Gamble and Rating Scale.
Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic Compartment.
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity.
CLIPPERS complicating multiple sclerosis causing concerns of CNS lymphoma.
Plasma ubiquitin?proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease.
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Fumaric acid esters prevent the NLRP3 inflammasome-mediated and ATP-triggered pyroptosis of differentiated THP-1 cells.
The use of cytokine signature patterns: separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients.
Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
Cervical cord and ventricle affection in neuromyelitis optica.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Measuring participation as defined by the World Health Organization in the International Classification of Functioning, Disability and Health. Psychometric properties of the Ghent Participation Scale.
Drugs@FDA
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].

Pages